KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Shares Outstanding (Weighted Average) (2016 - 2026)

Idexx Laboratories has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $80.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 2.47% year-over-year to $80.4 million; the TTM value through Dec 2025 reached $80.4 million, down 2.47%, while the annual FY2025 figure was $80.4 million, 2.47% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $80.4 million at Idexx Laboratories, roughly flat from $80.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $85.5 million in Q1 2021 and troughed at $80.4 million in Q4 2025.
  • A 5-year average of $83.2 million and a median of $83.1 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 0.22% in 2021 and later fell 2.47% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $85.2 million in 2021, then dropped by 1.85% to $83.6 million in 2022, then fell by 0.67% to $83.1 million in 2023, then decreased by 0.72% to $82.5 million in 2024, then dropped by 2.47% to $80.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IDXX at $80.4 million in Q4 2025, $80.6 million in Q3 2025, and $80.9 million in Q2 2025.